Page last updated: 2024-12-10

5,15-dihydroxy-6,8,11,13-eicosatetraenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,15-dihydroxy-6,8,11,13-eicosatetraenoic acid: RN given refers to (6,13-trans) & (8,11-cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5(S),15(S)-DiHETE : A DiHETE that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroxy substituents are placed at the 5S- and 15S-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283158
CHEBI ID91286
SCHEMBL ID1476432
MeSH IDM0107318

Synonyms (36)

Synonym
(5s,6e,8z,11z,13e,15s)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid
5(s),15(s)-dihete
5s,15s-dihete
LMFA03060010
5s,15s-dihydroxy-6e,8z,11z,13e-eicosatetraenoic acid
NCGC00161258-01
5(s),15(s)-dihydroxy-6,13-trans-8,11-cis-eicosatetraenoic acid
BML1-D01
SCHEMBL1476432
82200-87-1
6,8,11,13-eicosatetraenoic acid, 5,15-dihydroxy-, (s-(r*,r*-(e,e,z,z)))-
5,15-dihydroxy-6,8,11,13-eicosatetraenoic acid
6,8,11,13-eicosatetraenoicacid, 5,15-dihydroxy-, (5s,6e,8z,11z,13e,15s)-
(5s,15s)-dihydroxy-(6e,8z,11z,13e)-icosatetraenoic acid
(5s,15s)-dihydroxy-(6e,8z,11z,13e)-eicosatetraenoic acid
(5s,6e,8z,11z,13e,15s)-5,15-dihydroxyicosatetraenoic acid
5,15-dihydroxyeicosatetraenoic acid
CHEBI:91286
6,8,11,13-eicosatetraenoicacid,5,15-dihydroxy-,(5s,6e,8z,11z,13e,15s)-
eicosanoids_5,15-dihete_c20h32o4
5,15-dihydroxyeicosatetraenoate
5,15-dihydroxy-6,8,11,13-eicosatetraenoate
5s,15s-dihydroxy-6e,8z,11z,13e-eicosatetraenoate
Q27163191
SR-01000946935-1
sr-01000946935
5(s),15(s)-dihydroxy-6(e),8(z),10(z),13(e)-eicosatetraenoic aci
5s,15s-dihydroxy-6e,8z,10z,13e-eicosatetraenoic acid
CS-0062389
5(s),15(s)-dihete lipid maps(r) ms standard
HY-113492
5(s)15(s)-dihete
(5s,6e,8z,11z,13e,15s)-5,15-dihydroxy-6,8,11,13-eicosatetraenoic acid
DTXSID401157454
AKOS040755963
PD018249

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves have shown that the enzyme release proceeded in parallel with increments in cyclic AMP, suggesting a linkage between cyclic AMP and leukotriene B4-induced leukocyte activation."( Relationship of cyclic-AMP levels in leukotriene B4-stimulated leukocytes to lysosomal enzyme release and the generation of superoxide anions.
Claesson, HE; Feinmark, SJ, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
rat metaboliteAny mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus).
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxyicosatetraenoic acidA hydroxy fatty acid that is any eicosatetraenoic acid bearing two hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Arachidonic acid (AA, ARA) oxylipin metabolism076

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (42.31)18.7374
1990's11 (42.31)18.2507
2000's1 (3.85)29.6817
2010's2 (7.69)24.3611
2020's1 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.52 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]